Animal Allergies

Food Allergies

Allergy, Immunology, and ENT

Cardiovascular Diseases

Cardiology

Acne

Atopic Dermatitis

Dermatology

Emergency Medicine

Diabetes

Endocrinology

Formula

Nutrition

Obesity

Gastroenterology

Antibiotic Resistance

Bacterial Conjunctivitis

COVID-19

Influenza

Pneumonia

Sexually Transmitted Diseases

Vaccination and Immunization

Vaccines

Infectious Diseases

ADHD

Addiction

Antisocial Personality Disorder

Anxiety

Autism

Depression

Developmental/Behavioral Disorders

Psychiatry

Mental, Behavioral and Development Health

Concussion

Epilepsy

Headache

Neurology

Neonatal/Perinatology

OB/GYN

Pain

Drug Pipeline News

Pharmacology

Telemedicine

Practice Improvement

Asthma

Cystic Fibrosis

Respiratory

Rheumatology

News 

All News

PNP Corner

AAP News

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown State University in Youngstown, Ohio in 2020 with a degree in telecommunications and journalism. He started his career as a news and sports videographer before becoming an on-air sports anchor at the NBC-affiliated news station in Youngstown. Fitch briefly worked as a national content writer for a Chicago-based national television station before joining the 

team. He can be reached at: jfitch@mjhlifesciences.com.

Articles

 and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

 You can reach her at mpetronelli@mjhlifesciences.com.

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors

Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report. 

Surge in pediatric Mycoplasma pneumoniae hospitalizations reported in 2024

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination

Andrew Alexis, MD, MPH, Professor of Clinical Dermatology and Vice Chair for Diversity and Inclusion in the Department of Dermatology at Weill Cornell Medicine, a dermatologist at New York-Presbyterian/Weill Cornell Medical Center and lead ADmirable investigator. 

Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts. 

Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis

Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics – Clinical News & Pediatrician Practice Tips

Facebook

LinkedIn

Instagram

Clinical

Gynecology

Infectious disease

Mental Health

Oncology

Rheumatoid Arthritis

Sexual Health

View More

1rem

Authors

The incidence of childhood melanoma is increasing. There is evidence that cumulative exposure to ultraviolet radiation from the sun in the first 18 years of life contributes to the development of future skin cancers.

Ultraviolet radiation exposure and melanoma

**Editor's Note** Please note that starting January 1, 2025, we will be switching to an online-exclusive publication process. This will allow us to publish case submissions quicker without having to deal with the variables that come along with print publication. All cases will still be eligible for print publication consideration, but publication in our print magazine is not guaranteed and will be up to the editor's discretion. 

Do you have a puzzling pediatric case that you’d like to share with the readers of 

We are looking for intriguing diagnoses that have stumped the experts—a diagnostic “Puzzler”—to help our physicians enhance their day-to-day practices. If you have such a story to tell, tell us.

Here’s what to do: Before you begin, we suggest that first you review the Puzzler 

https://www.contemporarypediatrics.com/case-studies

. Please note the specific style required for writing Puzzler manuscripts.

Next, prepare a draft of your case, including a summary of the presenting symptoms, a case overview, a 

table of the differential diagnosis (MANDATORY)

, and the special aspects of your case that qualify it as a Puzzler, and send it to us. Please note that the differential diagnosis table should also be discussed in the body text. We’ll review your draft and let you know what you need to add or revise before we send the manuscript to peer review for evaluation.

Puzzlers vary in length, and we suggest a minimum of 1,200 words up to a maximum of 2,000 words, but that is because of the complexity of some cases and whether some patients returned for many assessments before their diagnoses were determined. Also, some authors describe the pathophysiology of the differentials in great detail. Please also note no more than 3 authors are allowed per article.

What's most important is to show us the process that you used to analyze the case, including:

Why you decided to order certain tests and why you did not order others.

Peer consultations or why you elected to contact other specialists.

Lab values including vital signs or blood tests.

Labs and values if your patient was attended to in the emergency department or other hospital departments such as radiology or neurology.

Discussion related to the possible diagnoses.

Final diagnosis, treatment, prognosis, and follow-up.

Remember to indicate numbered citations within the body of the text and include a complete list of corresponding literature/references at the end of the manuscript. (Do not use any citation management programs or unlink them.) 

Limit references to 25. No references (unless it is a seminal study) can be older than 10 years.

We prefer primary research as references, but some cases are so obscure that authors will need to pull from a variety of sources. However, 

. Be advised that peer reviewers are adamant that the disease/disorder you describe was actually diagnosed and not determined by index of suspicion on the basis of ruling out various differentials. We use AMA11 as our publication style, which uses superscript citation numbers and a corresponding numbered reference list. Please create your citations and references in this style.  Check this recent article posted online at 

https://www.contemporarypediatrics.com/view/the-rx-of-adhd

 for examples of reference style. IMPORTANT NOTE WITH AMA 11TH EDITION: PLEASE PUT DOI OR WEBSITES/URLS AT THE END OF THE REFERENCE LINE.

When you send your draft manuscript, also 

. These image files must be high-resolution jpg or tiff files (minimum of 300 dpi) and as large in size as possible. We suggest a minimum of 7 horizontal inches. The images must be original photos with clear permissions to use, not images from copyrighted sources. Send as separate attachments with your e-mail submission; do not embed images into your manuscript document.

After we receive your manuscript, our editors and peer reviewers will review your draft and let you know if we accept your submission for publication. 

Puzzler is one of the departments for which we receive the most submissions, so it may be several months after submission before you receive feedback from us.

If we do accept your submission for publication, we will contact you with further instructions.

Send your submissions in Microsoft Word format to 

, via e-mail to mpetronelli@mjhlifesciences.com

Guidelines for PUZZLER, Contemporary Pediatrics

Another month has come and gone, and with it, several FDA approvals and regulatory updates related to the ever-evolving landscape of pediatric health care.

In our May monthly recap, we list our top FDA-related news items so you can stay informed in an easy-to-read and quick format.

Take a look at our detailed coverage of FDA-related news from May, and easily stay in touch with 

 that bring you practical information for today's pediatrician.

Click the title of each story below for our full coverage of that regulatory update.

1. INF108 to prevent necrotizing enterocolitis receives FDA designations

On May 7, 2025, Infinant Health announced that INF108, its investigational drug for necrotizing enterocolitis (NEC) prevention in preterm infants, received orphan drug and rare pediatric disease designations from the FDA.

These designations aim to support the development of INF108 for NEC, a life-threatening intestinal condition that affects 7% of very low birth weight infants in NICUs. The company plans to initiate clinical trials to evaluate INF108 in preterm infants.

2. FDA clears EN-374 therapy application for X-linked chronic granulomatous disease

On May 12, 2025, the FDA cleared an investigational new drug (IND) application for Ensoma’s EN-374, a first-in-class in vivo gene therapy for X-linked chronic granulomatous disease (X-CGD).

EN-374 uses virus-like particles to deliver a CYBB transgene directly to hematopoietic stem cells, aiming to restore immune function in X-CGD patients. The therapy, which received orphan drug and rare pediatric disease designations, will enter a Phase 1/2 trial in late 2025.

FDA approves pediatric indication for Optison ultrasound enhancing agent

On May 13, 2025, the FDA approved GE HealthCare’s Optison (Perflutren Protein-Type A Microspheres) for pediatric use to enhance echocardiogram clarity.
Already approved for adults, Optison now helps improve visualization of left ventricular structures in children with suboptimal echocardiograms, aiding cardiac diagnosis.

4. FDA starts review of nutrients in infant formula

On May 13, 2025, the FDA and HHS issued a request for information to begin a comprehensive review of infant formula nutrients under "Operation Stork Speed."
This marks the first full review since 1988 and aims to update nutrient standards, enhance transparency, and improve formula safety and effectiveness for U.S. infants.

5. FDA seeks to remove ingestible fluoride products for children

On May 13, 2025, the FDA and HHS announced plans to remove pediatric ingestible fluoride prescription drugs from the market due to safety concerns.
Citing links to gut microbiome disruption and thyroid disorders, the FDA will review evidence and seek public comment by October 31, 2025, before taking action.

6. FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years

On May 14, 2025, the FDA accepted a new drug application for berotralstat (ORLADEYO) for the treatment of hereditary angioedema in children aged 2 to 11, with priority review.

If approved, berotralstat would become the first targeted oral prophylactic therapy for pediatric HAE patients, with a decision expected by September 12, 2025.

7. FDA approves NVX-CoV2705 COVID-19 vaccine

On May 19, 2025, the FDA approved Novavax’s NVX-CoV2705 (Nuvaxovid), the only protein-based, non-mRNA COVID-19 vaccine in the United States, for at-risk patients.
The vaccine is indicated for individuals aged 12 to 64 with underlying conditions and all adults 65 and older, based on phase 3 trial data showing strong safety and efficacy.

8. FDA approves Jivi for patients aged 7 years and older with hemophilia A

On May 19, 2025, the FDA approved Jivi (antihemophilic factor [recombinant], PEGylated-aucl; Bayer) for children aged 7 to <12 with hemophilia A.
This expanded indication is based on clinical trial data showing Jivi’s safety and efficacy in reducing bleeding episodes in pediatric patients with severe disease.

9. FDA approves roflumilast foam 0.3% for scalp, body psoriasis

On May 22, 2025, the FDA approved roflumilast (Zoryve) topical foam 0.3% to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.
In phase 2 and 3 trials, the foam demonstrated significant improvements in psoriasis symptoms, including rapid itch relief, with strong safety and tolerability data.

10. FDA approves MenQuadfi meningococcal vaccine for children 6 weeks or older

On May 23, 2025, the FDA expanded the approval of MenQuadfi (Sanofi) to include infants aged 6 weeks to 23 months for the prevention of meningococcal disease.

MenQuadfi is now the only quadrivalent MenACWY vaccine approved for use from 6 weeks of age, with data showing comparable safety and immune response to existing vaccines.

11. FDA approves hydrocortisone oral solution for children 5 years, older with adrenocortical insufficiency


On May 28, 2025, the FDA approved Eton Pharmaceuticals’ hydrocortisone oral solution (Khindivi) for pediatric patients aged 5+ with adrenocortical insufficiency.

Khindivi is the first FDA-approved hydrocortisone oral solution, offering precise, ready-to-use dosing tailored for children without the need for tablet splitting.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from May 2025.

News

FDA news in pediatrics: May 2025

RX Review: RSV prevention and pediatric hospitalization

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent advancements in RSV prevention, including maternal vaccination and long-acting monoclonal antibodies, are beginning to shift the clinical conversation from reactive management to proactive protection. In this HCP Live Network RX Review roundtable, moderator Albert Rizzo, MD, chief medical officer of the American Lung Association, leads a discussion on the evolving RSV landscape, with a focus on what these advances mean for pediatric care.

Rizzo is joined by 2 expert panelists: Tina Tan, MD, a pediatric infectious disease physician and professor of pediatrics at Northwestern University’s Feinberg School of Medicine; and Joanne Nazif, MD, a pediatric hospitalist at Children’s Hospital at Montefiore and associate professor of pediatrics at Albert Einstein College of Medicine.

In this first installment of a 3-part video series, Tan describes the impact of new preventive tools on clinical practice. She notes that both the RSV vaccines and monoclonal antibody nirsevimab have significantly reduced RSV-related hospitalizations and disease severity in infants, especially during the second year following nirsevimab’s introduction. Tan emphasizes the protective effect of maternal vaccination, which has shown promise in shielding newborns from RSV in the early months of life. However, she also points out that uptake among older adults remains low, resulting in continued hospitalizations for severe RSV infections in that population.

Nazif brings a hospitalist’s perspective, highlighting that while preventive options have improved, therapeutic approaches for RSV remain largely unchanged. Supportive care is still the cornerstone of treatment, as various pharmacologic interventions—including bronchodilators and hypertonic saline—have not demonstrated consistent benefits. This makes prevention all the more essential.

The panel also reviews epidemiologic shifts since the COVID-19 pandemic. While RSV hospitalizations declined during the peak pandemic years, recent seasons have seen a return to pre-pandemic trends. Importantly, early data from the 2024–2025 season—marking the first widespread availability of both maternal RSV vaccine and nirsevimab—show a notable decline in infant RSV hospitalizations, particularly in babies under 2 months of age. This is a promising indication of the real-world value of these interventions.

This expert discussion sets the stage for deeper exploration of RSV management and prevention, arming clinicians with timely insights to improve outcomes for pediatric patients.

 is a professor of pediatrics at the Feinberg School of Medicine at Northwestern University and an infectious disease physician. She is also medical director of the International Patient and Destination Services Program, president of the Lurie medical dental staff at Ann & Robert H. Lurie Children’s Hospital of Chicago, and president of the Infectious Disease Society of America.

 is chief medical officer of the American Lung Association. Board certified in internal medicine, pulmonary, critical care and sleep medicine, Rizzo serves as the moderator for this panel discussion.

 is an attending physician in the division of Hospital Medicine at Children's Hospital at Montefiore. She also serves as an associate professor of pediatrics at Albert Einstein College of Medicine.

Rizzo, Tan, and Nazif report no relevant disclosures.

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

Video Series

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD joined us to discuss the importance of this newly FDA-approved topical treatment for scalp and body psoriasis patients aged 12 years and older. 

Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%

FDA approved roflumilast (Zoryve; Arcutis Biotherapeutics) foam 0.3%

 to treat plaque psoriasis of the scalp and body in individuals aged 12 and older. Jennifer Soung, MD, director of clinical research at Southern California Dermatology and a clinical trial investigator, joined us to break down the approval and the impact it can have in the psoriasis treatment landscape.

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.

Abha Gupta, MD

Articles

Latest Updated Articles